Yayın:
Implications of NLRP3 suppression using glibenclamide and miR-223 against colorectal cancer

dc.contributor.authorHamza, Shaimaa
dc.contributor.authorGaranina, Ekaterina E.
dc.contributor.authorShkair, Layaly
dc.contributor.authorAlsaadi, Mohammad
dc.contributor.authorKhaiboullina, Svetlana F.
dc.contributor.authorTezcan, Gülçin
dc.contributor.buuauthorTEZCAN, GÜLÇİN
dc.contributor.departmentDiş Hekimliği Fakültesi
dc.contributor.departmentTemel Bilimler Bölümü
dc.contributor.researcheridJJL-1176-2023
dc.date.accessioned2025-01-28T07:38:51Z
dc.date.available2025-01-28T07:38:51Z
dc.date.issued2024-03-01
dc.description.abstractThe NLR family pyrin domain containing 3 (NLRP3) promotes the growth of colorectal cancer (CRC). However, the therapeutic effect of NLRP3 inhibition on CRC cell progression is controversial. This study comparatively investigated the therapeutic effect of a pharmacological NLRP3 inhibitor, glibenclamide (gli), and the post-translational suppression of NLRP3 by miR-223 on CRC cell progression in HCT-116 and HCT-15 cells. LPS and ATP were used to activate Gli-treated and LSB-hsa-miR-223-3p (WTmiR-223)-expressing HCT-116 cells. NLRP3.AB.pCCL.sin.cPPT.U6.miR-223-Decoy.hPGK.GFP.WPRE plasmid (DmiR-223) was the negative control for miR-223 expression. NLRP3, gasdermin D, and BAX expressions were analyzed using western blotting. Real-time PCR detected the RNA expression of autophagy-related genes ATG5, BECN1, and miR-223 in non-transfected cells. ELISA analyzed IL-1 beta and IL-18 in the medium. MTS-1, annexin V, wound-healing, and sphere-invasion assays were used to assess cell viability and progression. A multiplex cytokine assay detected proinflammatory cytokine secretion. LPS-ATP-activated NLRP3 produced gasdermin D cleavage, released IL-1b and IL-18, and activated cell migration and sphere invasion. In contrast, reduced cell growth, miR-223 expression, IFN-gamma, CXCL10, and LIF secretion were found in cells after inflammasome activation. Both gli and WTmiR-223 induced autophagy genes ATG5 and BECN1 and reduced the NLRP3 activation and its downstream proteins. However, while gli had a limited effect on the production of IFN-gamma, CXCL10, and LIF, WTmiR-223 increased the release of those cytokines. In addition, gli did not suppress cell growth, while WTmiR-223 promoted apoptosis. Notably, neither gli nor WTmiR-223 effectively prevented sphere invasion. These data suggest that, while WTmiR-223 could have a better anticancer effect in CRC compared to gli, the sole usage of miR-223-mediated NLRP3 suppression may not be sufficient to prevent CRC metastasis.
dc.description.sponsorshipKazan Federal University Strategic Academic Leadership Program
dc.identifier.doi10.3390/ph17030299
dc.identifier.issue3
dc.identifier.scopus2-s2.0-85189030707
dc.identifier.urihttps://doi.org/10.3390/ph17030299
dc.identifier.urihttps://www.mdpi.com/1424-8247/17/3/299
dc.identifier.urihttps://hdl.handle.net/11452/49864
dc.identifier.volume17
dc.identifier.wos01193006600001
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherMdpi
dc.relation.journalPharmaceuticals
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectInflammasome activation
dc.subjectGrowth-factor
dc.subjectInhibition
dc.subjectReceptor
dc.subjectMechanism
dc.subjectAutophagy
dc.subjectCells
dc.subjectProliferation
dc.subjectSulfonylureas
dc.subjectMicrorna-223
dc.subjectNlrp3
dc.subjectInflammasome
dc.subjectGlibenclamide
dc.subjectMicrorna-223
dc.subjectColorectal cancer
dc.subjectMetastasis
dc.subjectPharmacology & pharmacy
dc.titleImplications of NLRP3 suppression using glibenclamide and miR-223 against colorectal cancer
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentDiş Hekimliği Fakültesi/Temel Bilimler Bölümü
local.indexed.atWOS
local.indexed.atScopus
relation.isAuthorOfPublicatione171a866-0a2e-4df4-9f4b-d9058971c979
relation.isAuthorOfPublication.latestForDiscoverye171a866-0a2e-4df4-9f4b-d9058971c979

Dosyalar

Orijinal seri

Şimdi gösteriliyor 1 - 1 / 1
Küçük Resim
Ad:
Tezcan_vd_2024.pdf
Boyut:
3.67 MB
Format:
Adobe Portable Document Format